Aaron R Hochberg

Dr. Aaron R Hochberg

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2025 in International Journal Of Impotence Research
Verified
Journal Article
Open access
PDF file
BIBrian H. Im
Brian H. Im
AHAaron R Hochberg
Aaron R Hochberg
AGAnalyse H. Giordano
Analyse H. Giordano
RERachel Evans
Rachel Evans
AFAndrzej Fertala
Andrzej Fertala
PCPaul H Chung
Paul H Chung
Hydrophilic penile prosthesis (PP) surfaces removed during revision surgery may potentially rebind antiseptics and maintain antimicrobial efficacy ex vivo. Coloplast Titan reservoirs and cylinders were retrieved during revision surgery for mechanical failure. Congo Red staining and contact angle measurements were performed to evaluate the integrity of the hydrophilic surface. Fluorescent antibiotic binding was performed by submerging discs for 3 min in either fluorescein-isothiocyanate (FITC) labeled or unlabeled vancomycin at 2 mg/mL. Fluorescence was quantified via ImageJ. 8 mm discs were submerged for 3 min in normal saline (NS), 0.05% chlorhexidine gluconate, or a 2 mg/mL vancomycin and 160 μg/mL gentamicin (VG) antibiotic, then incubated with 10 5 colony-forming units per milliliter of methicillin-sensitive Staphylococcus aureus ATCC25923 for 48 h then counted. Mann-Whitney U and one-way ANOVA tests were performed to compare outcomes, p < 0.05 considered significant. All PP tested for binding with FITC-vancomycin showed significant increases in fluorescence relative to unlabeled vancomycin controls (p < 0.0001). All explanted and control PP exhibited significant decreases in bacterial counts on VG-treated surfaces relative to NS controls (p < 0.01). The hydrophilic surface of the reservoir and cylinders maintain their integrity based on Congo Red staining and rebind VG antibiotics effectively based on microbiology and fluorescent binding studies.

6 September 2024 in Urology Practice
Verified
Journal Article
Closed access
MSMihir Shah
Mihir Shah
AHAaron R Hochberg
Aaron R Hochberg
ZPZachary James Prebay
Zachary James Prebay
YSYash B Shah
Yash B Shah
BIBrian H. Im
Brian H. Im
CLCostas D. Lallas
Costas D. Lallas
Placing ureteral stents at the uretero-ileal anastomosis for radical cystectomy with ileal conduit (RCIC) has long been common practice. Recently, some providers have begun omitting stents. We sought to investigate differences in perioperative and 30-day outcomes between patients who underwent radical cystectomy with ileal conduit (RCIC) with and without stents placed at the uretero-ileal anastomosis. We identified RCICs performed between 2019 to 2021 in the National Surgical Quality Improvement Program database and corresponding Cystectomy-Targeted Participant Use File. Baseline demographics, comorbidities, and operative parameters were compared via Pearson's chi-square and t-tests between stented and stent-less RCICs. Outcomes of interest, including rates of urinary tract infections (UTIs), acute kidney injury (AKI), renal failure requiring dialysis, ileoileal anastomotic leaks, ureteral obstruction, urinary leak or fistula formation, reoperations, and 30-day hospital readmissions were compared using Pearson's chi-square. All statistical tests were 2 tailed with P < .05 considered significant. Five Thousand Four Hundred Eighteen RCICs were identified. Four hundred ninety-eight (9.2%) were stent-less. There were no differences in baseline demographics or comorbidities. Significantly fewer stented patients had robotic-assisted operations (23% vs 29%, P < .01). Stented patients had lower rates of urinary leak or fistula formation (3.1% vs 4.8%, P = .04). There was no significant difference in 30-day rates of UTIs, AKIs, renal failure, ileoileal anastomotic leaks, ureteral obstruction, reoperations, and readmissions. Limitations include retrospective design and lack of longitudinal tracking past 30 days. Stent-less patients had non-inferior outcomes compared to stented patients in most important 30-day outcomes. Our analysis suggests that stents may not be necessary in ileal conduit urinary diversion procedures.

1 February 2026 in JU Open Plus
Verified
Journal Article
Open access
PCPaul H Chung
Paul H Chung
BBBen Boursi
Ben Boursi
HBHarel Baris
Harel Baris
JLJoon Yau Leong
Joon Yau Leong
JNJ. Curtis Nickel
J. Curtis Nickel
CPCaleb D. Phillips
Caleb D. Phillips
Introduction: Space travel exposes crew to substantial stressors, which may potentially alter their microbiome and be detrimental to their health and safety. We hypothesize that urinary microbiota is altered during a short-duration spaceflight to the International Space Station (ISS). Methods: Urine samples were collected from 4 male crew members. One crew member provided samples while on orbit on the ISS using a urine collection kit (UCK) designed for low-gravity environments. This crew member also provided paired mid-stream and UCK samples on Earth prelaunch and on return for direct comparison of collection methods. Three additional crew members provided mid-stream samples prelaunch and on return, and also for follow-up timepoints to serve as ex post facto control samples. Urine was stored at −80℃ and sent for 16s next-generation sequencing (MicroGenDX, Lubbock, TX). Results: Bacterial load ( P = .52), species richness ( P = .64), and differences in microbiota composition ( P = .26) did not significantly vary by the collection method (mid-stream vs UCK). Significant differences in species richness, load, and microbial composition among preflight, orbital, and return mission samples were detected ( P = .047, F = 1.8092, df = 2.9, R2 = 0.34076). Orbital microbial composition significantly differed from preflight ( P = .03) and return ( P = .03), whereas preflight and return samples did not differ ( P > .05). Comparison with the limited follow-up ex post facto Earth-bound samples serving as controls showed no significant differences among preflight or return mission samples, but preflight ( P = .04) and return ( P = .05) did significantly differ compositionally from orbital samples. Continuous temporal effects on composition were evaluated through which bacterial load ( P = .05) was statistically significant, peaking during the orbital period. Conclusions: Results are consistent with an effect of space travel altering the urinary microbiota. Further studies are needed to confirm this result and to better understand whether such changes may be detrimental to the health and safety of space travelers and professional astronauts.

29 January 2025 in International Journal Of Impotence Research
Verified
Journal Article
Open access
PDF file
ZPZachary James Prebay
Zachary James Prebay
DFDavid Fu
David Fu
AHAaron R Hochberg
Aaron R Hochberg
PCPaul H Chung
Paul H Chung
Prostate cancer treatment-related erectile dysfunction and stress urinary incontinence are commonly treated with inflatable penile prosthesis (IPP) or artificial urinary sphincter (AUS). Given the association with androgens and penile/urethral health, we aim to evaluate whether patients on androgen deprivation therapy (ADT) undergoing IPP or AUS surgery are at increased risk for reintervention, complication, or infection. We queried the TriNetX database for adult males receiving IPP or AUS. The ADT cohort included those on ADT 3 months before or any time after surgery. We performed sub-analysis for leuprolide and bicalutamide. Cohorts and outcomes were defined by Current Procedural Terminology and International Classification of Diseases codes. Propensity score matching was performed using age, prostate cancer, history of prostatectomy, and history of radiation. Outcomes were reintervention (revision, removal, or replacement), infection, and complication. Analytics were performed in March 2024. 13,432 patients received an IPP and 5676 received an AUS, 465 and 745 of whom were on ADT, respectively. The only significant AUS analysis was for patients on abiraterone having fewer reinterventions (10.5% vs 20.8%, RR = 0.50 [0.29, 0.88]). Patients receiving an IPP with ADT had fewer reinterventions (7.2% vs 12%, RR = 0.60 [0.39, 0.92]) and complications (12.7% vs 18.5%, RR = 0.68 [0.49, 0.95]). Those on a GnRH agonist had fewer reinterventions (7.4% vs 11.7%, RR = 0.63 [0.41, 0.98]) for IPP. Patients receiving an IPP on bicalutamide had fewer reinterventions ( <5.2%* vs 10.8%, RR = 0.48 [0.23, 0.99]) and on leuprolide had fewer complications (12.2% vs 19.3%, RR = 0.63 [0.43, 0.91]). The remainder of analyses showed no significant differences. Patients with IPP or AUS do not fare worse on ADT. Further evaluation into the duration of ADT may provide clinical context, but based on these results, ADT should not limit implant surgery.

8 May 2025 in Cancers
Verified
Journal Article
Open access
PDF file
AHAaron R Hochberg
Aaron R Hochberg
AHAnnie Huiwen Ho
Annie Huiwen Ho
RTRasheed A.M. Thompson
Rasheed A.M. Thompson
MBMatthew B. Buck
Matthew B. Buck
CLCostas D. Lallas
Costas D. Lallas
MSMihir Shah
Mihir Shah
Prostate cancer (CaP) remains the most diagnosed malignancy in men, and the incidence of high-grade disease at diagnosis is increasing

1 April 2026 in JU Open Plus
Verified
Journal Article
Open access
PCPaul H. Chung
Paul H. Chung
BBBen Boursi
Ben Boursi
HBHarel Baris
Harel Baris
JLJoon Yau Leong
Joon Yau Leong
JNJ. Curtis Nickel
J. Curtis Nickel
CPCaleb D. Phillips
Caleb D. Phillips